

Supplementary Materials, Annex Table 1. Baseline characteristics aggregated into GEP-NENs and NGEP-NENs.

Baseline Characteristic	All patients, N=522 (100%)	GEP-NEN, N=390 (100%)	NGEP-NEN, N=132 (100%)
Gender			
Men	314 (60.2)	231 (59.2)	83 (62.9)
Women	208 (39.8)	159 (40.8)	49 (37.1)
Age (years), median (range)	60 (21-88)	61 (21-88)	59 (21-83)
ECOG performance status			
0	256 (49.0)	202 (51.8)	54 (40.9)
1	210 (40.2)	148 (37.9)	62 (47.0)
2	37 (7.1)	27 (6.9)	10 (7.6)
>2	4 (0.8)	2 (0.5)	2 (1.5)
Unknown	15 (2.9)	11 (2.8)	4 (3.0)
Primary tumor site			
Pancreatic	182 (34.8)	182 (46.7)	-
Small intestine	153 (29.3)	153 (39.2)	-
Colorectum	24 (4.1)	24 (6.2)	-
Esophagogastric	9 (1.7)	9 (2.3)	-
Other GEP	11 (2.1)	11 (2.8)	-
Unknown primary of digestive origin	11 (2.1)	11 (2.8)	-
Lung	56 (10.7)	-	56 (42.4)
Pheochromocytoma	9 (1.7)	-	9 (6.8)
Paranglioma	22 (4.2)	-	22 (16.7)
Thymus	4 (0.7)	-	4 (3.0)
Thyroid	2 (0.3)	-	2 (1.5)
Unknown origin	32 (6.1)	-	32 (24.2)
Other NGEP	7 (1.3)	-	7 (5.3)
Ki-67, median (range)	5 (0-80)	5 (1-80)	7 (0-77)
Missing	95 (18.2)	56 (14.4)	39 (29.5)
Grade (WHO 2017)			
NET G1	178 (34.1)	138 (35.4)	40 (30.3)
NET G2	292 (55.9)	216 (55.4)	76 (57.6)
NET G3	42 (8.0)	30 (7.7)	12 (9.1)
NEC G3	10 (1.9)	6 (1.5)	4 (3.0)
Hormonal syndrome	169 (32.4)	125 (32.1)	44 (33.3)
Localization of metastases			
Liver	436 (83.5)	350 (89.7)	86 (65.2)
Lymph nodes	286 (54.8)	208 (53.3)	78 (59.1)
Peritoneum	90 (17.2)	77 (19.7)	13 (9.8)
Bone	145 (27.8)	77 (19.7)	68 (51.5)
Lung	48 (9.2)	20 (5.1)	28 (21.2)
Other	78 (14.9)	52 (13.3)	26 (19.7)
Prior surgery			
Primary tumor	281 (53.8)	208 (53.3)	73 (55.3)
Metastases	121 (23.2)	104 (26.7)	17 (12.9)
Number of prior systemic treatments			
0	22 (4.2)	5 (1.3)	17 (12.9)
1	184 (35.2)	150 (38.5)	34 (25.8)
2	144 (29.7)	119 (30.5)	36 (27.3)
>2	161 (30.8)	116 (29.7)	45 (34.1)
Prior systemic treatments			
Somatostatin analogues	477 (91.4)	371 (95.1)	106 (80.3)
Chemotherapy	144 (27.6)	96 (24.6)	48 (36.4)
Everolimus	224 (42.9)	169 (43.3)	55 (41.7)
Sunitinib	104 (19.9)	83 (21.3)	21 (15.9)
Other tyrosin quinase inhibitor	54 (10.3)	36 (9.2)	18 (13.6)

Prior locoregional and ablative therapies	77 (14.8)	69 (17.7)	8 (6.1)
Median time from initial diagnosis to PRRT, months (range)	40.6 (0-288)	40.3 (0-288)	41 (1.8-273)
Median time from most recent progression until PRRT, months (range)	2.3 (0-92.1)	2.3 (0-92)	2.5 (0-2)
SRI, Krenning scale			
2	44 (8.4)	28 (7.2)	16 (12.1)
3	395 (75.7)	304 (77.9)	91 (68.9)
4	83 (15.9)	58 (14.9)	25 (18.9)
[¹⁸F]F-FDG PET-CT			
Not done	383 (73.4)	302 (77.4)	81 (61.4)
Consistent with SRI	50 (9.6)	24 (6.2)	26 (19.7)
Not concordant	89 (17.0)	64 (16.4)	25 (18.9)

Abbreviations: GEP, gastroenteropancreatic; NGEP, no gastroenteropancreatic; ECOG, Eastern Cooperative Oncology Group; WHO, World Health Organization; PRRT, peptide receptor radionuclide therapy; PET, Positron emission tomography; SRI, somatostatin receptor-based imaging; 18F-fluorodeoxyglucose position emission tomography-computed tomography; NET, neuroendocrine tumor; NEC, neuroendocrine carcinoma.